In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.
Pathogen inactivation using the INTERCEPT Blood System requires platelet resuspension in InterSol and reduced plasma. Platelets in plasma collected on the Haemonetics MCS+ were processed on the INTERCEPT Preparation Set for plasma volume reduction and addition of InterSol. The use of the Preparation Set resulted in a mean platelet loss of 5.6 +/- 3.4%. Subsequent photochemical treatment (PCT) with amotosalen and ultraviolet A light, and 7 days of storage, resulted in acceptable changes for platelet swirling, lactate, lactate dehydrogenase (LDH), platelet factor-4 (PF4), p-selectin, glycoprotein V (GpV), pO2, pCO2, tumour necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8). All platelet units processed with the Preparation Set and PCT met European requirements for leucoreduction and pH values.
Isola
H
H
EFS-Alsace, Strasbourg, France.
Kientz
D
D
Aleil
B
B
Laeuffer
P
P
Weil
J
J
Wiesel
M-L
ML
Laforêt
M
M
Lin
L
L
Mayaudon
V
V
Cazenave
J-P
JP
D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D017848:Blood-Borne Pathogens / Q000528:radiation effects; D011564:Furocoumarins; D006801:Humans; D066298:In Vitro Techniques; D010777:Photochemistry; D017319:Photosensitizing Agents; D010953:Plasma Volume; D010983:Plateletpheresis / Q000295:instrumentation* / Q000379:methods; D012996:Solutions; D014466:Ultraviolet Rays
D011564:Furocoumarins; D017319:Photosensitizing Agents; D012996:Solutions; C118577:amotosalen